Oil India chief reveals plans of the upcoming IPO and future investment strategies.
Cipla tops pharma rankings with 5.42% market share, ahead of Ranbaxy and GSK.
The year 2007 surely belonged to the Indian gaming industry. Though investments made were larger than the returns, the number of people playing games certainly grew.
If you search for Benazir Bhutto on the Net, chances are that you would reach a malicious website that will steal your money and personal details stored on the computer and may even crash the system. All this if you do not have a genuine anti-virus installed on the PC.
Matrix's new SIM offering promises less paperwork.
Oil and Natural Gas Corporation (ONGC), the country's leading oil and gas exploration and production company, is entering the alternative energy segment with a Rs 1,200 crore-plus (Rs 12 billion) investment to generate 200 mw of wind power for captive use, within two years.
With 40 million diabetic patients and an equal number of people estimated to be diabetic prone, India is emerging as a major market for blood glucose monitoring solutions.
The declining prices of mobile handsets and low connectivity costs have helped in doubling Internet access through cellphones this year.
The Essar group firm is in talks with 7-10 companies for a "strategic fit", as it races to become a $500 million company by 2010. In some of these cases the due diligence process is in progress. Aegis is looking at firms in the US, South America and the Philippines.
Consider these numbers. The latest figures from the Telecom Regulatory Authority of India reveal that the number of Indians using their mobiles to logon to the internet has increased from 16 million in 2006 to 38 million in 2007 (both GSM and CDMA).
In another setback to Big Pharma, US drug major Eli Lilly's blockbuster erectile dysfunction drug Cialis (generic name:Tadalafil) has failed to qualify for a product patent in India after the basic constituent of the medicine was found to be a known substance, developed and patented by Indian scientists 32 years ago.
Interestingly, the European Patent Office is yet to grant a patent for Maraviroc, citing insufficient data, sources said. These were the main reasons cited by the Indian Patent Office for rejecting the patent for the cancer drug Gleevec, which snowballed into a global patent battle between the Swiss drug major Novartis and the Indian government.
Players such as Net4, Sify and Worldphone Internet Services are offering International long distance (ILD) calls that work out to less than a rupee a minute by using a technology called Voice over Internet Protocol (VoIP). Around 80 million minutes worth of calls are made via VoIP every month (legally), according to Telecom Regulatory Authority of India (TRAI).
Suzlon Energy, one of the top five wind energy manufacturers in the world, plans to raise $500 million (Rs 2,000 crore) through the Qualified Institutional Placement (QIP) route to fund its expansion plans.
The drug regulatory agencies of India and Canada are planning to collaborate on improving the quality of drugs traded between the two countries, besides helping the industry in both the countries to tap the opportunities in the field of generic medicines and drug development.
The effects of the sub-prime crisis and the resultant slowdown of the US market is evident on the margins of Indian information technology (IT) and IT-enabled Services (ITeS) firms. Business process outsourcing (BPO) firms such as Firstsource, Pune-based HOV Services, Zenta, Aegis BPO and others have been receiving inquiries from existing as well as new customers for ramping up their account receivables management (ARM) business.
The Indian pharmaceutical companies are involved in patent litigations of a mere 40 drugs, out of the 135 known patent litigation drugs in the US. This is despite the claims by major Indian players such as Ranbaxy and Dr Reddy's at having secured over 20 first to file status abbreviated new drug applications with the US Food and Drug Administration.
The company is demerging its new chemical entity research unit into a separate company to meet the demands of increased spend on research and development, and to insulate investors from the risks involved. According to the deal signed with Merck, NPIL will discover and develop new drugs for two selected targets provided by Merck in the area of cancer.
Players in the Indian animation industry, who primarily cater to movie studios in the US, are increasingly looking at the domestic market, especially after the commercial success of animated movie Hanuman. Of the total revenues generated by the Indian studios, approximately 70 per cent comes from outsourced work.
Generic drug sales in the US, that power the business of such leading Indian drug manufacturers as Ranbaxy, Dr Reddy's, Sun Pharma, Lupin and Zydus Cadila, will face competition soon, as big US wholesalers decide to outsource their requirements from upcoming Indian manufacturers.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances